congresses-banner
The content contained is subject
The content contained is subject to congress/journal copyright permissions. No further reproduction is permitted without permission of the copyright owner.
Information about pipeline compounds or investigational uses of compounds does not imply FDA approval for these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the pipeline compounds or investigational uses will receive FDA approval. Daiichi Sankyo does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.
Disease Area Tab
PublicationView
Poster
HER3-DXd
ASCO 2024 | May 31 - June 4, 2024
HERTHENA-PanTumor01: A global, multicohort, phase 2 trial of HER3-DXd in relapsed/refractory metastatic solid tumors
Poster
T-DXd
ASCO 2024 | May 31 - June 4, 2024
Trastuzumab deruxtecan in patients with HER2-expressing biliary tract cancer and pancreatic cancer: Outcomes from DESTINY-PanTumor02
Poster
T-DXd
ASCO 2024 | May 31 - June 4, 2024
Trastuzumab deruxtecan in patients with HER2-expressing bladder cancer: Outcomes from DESTINY-PanTumor02
Poster
T-DXd
ASCO 2024 | May 31 - June 4, 2024
Trastuzumab deruxtecan in patients with HER2-expressing head and neck tumors: Outcomes from DESTINY-PanTumor02